Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.
Jingsong Zhang, MD, PhD
Advertisement
Articles by Jingsong Zhang, MD, PhD
Jingsong Zhang, MD, PhD, discusses the advancements for patients with metastatic castration-resistant prostate cancer (mCRPC) that have occurred over the last decade.
Advertisement
Latest Updated Articles
Dr. Zhang on the State of Risk Stratification in mCRPCAugust 30th 2021
Dr. Zhang on Therapeutic Advancements in Prostate CancerOctober 6th 2016
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
5